After monumental MASH nod, Madrigal plots $600M stock sale to support Rezdiffra launch
Fierce Pharma
MARCH 19, 2024
Just a few days ago, Madrigal Pharmaceuticals made history by winning FDA approval for its metabolic dysfunction-associated steatohepatitis (MASH) med Rezdiffra. Now, the company looks to support the upcoming launch by selling shares.
Let's personalize your content